WO1997047734A1 - Differenciation et culture in vitro de cellules souches multipotentes de primates et usages therapeutiques - Google Patents

Differenciation et culture in vitro de cellules souches multipotentes de primates et usages therapeutiques Download PDF

Info

Publication number
WO1997047734A1
WO1997047734A1 PCT/US1997/010316 US9710316W WO9747734A1 WO 1997047734 A1 WO1997047734 A1 WO 1997047734A1 US 9710316 W US9710316 W US 9710316W WO 9747734 A1 WO9747734 A1 WO 9747734A1
Authority
WO
WIPO (PCT)
Prior art keywords
cells
stem cells
medium
pluripotent stem
culture
Prior art date
Application number
PCT/US1997/010316
Other languages
English (en)
Inventor
Roger A. Pedersen
Original Assignee
The Regents Of The University Of California
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by The Regents Of The University Of California filed Critical The Regents Of The University Of California
Priority to AU33926/97A priority Critical patent/AU3392697A/en
Publication of WO1997047734A1 publication Critical patent/WO1997047734A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0603—Embryonic cells ; Embryoid bodies
    • C12N5/0606—Pluripotent embryonic cells, e.g. embryonic stem cells [ES]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/90—Serum-free medium, which may still contain naturally-sourced components
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C12N2501/2306—Interleukin-6 (IL-6)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C12N2501/235—Leukemia inhibitory factor [LIF]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/237—Oncostatin M [OSM]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/30—Hormones
    • C12N2501/33—Insulin
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2502/00—Coculture with; Conditioned medium produced by
    • C12N2502/13—Coculture with; Conditioned medium produced by connective tissue cells; generic mesenchyme cells, e.g. so-called "embryonic fibroblasts"
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2503/00—Use of cells in diagnostics
    • C12N2503/02—Drug screening

Definitions

  • the field is isolation and culture of primate pluripotent stem cells.
  • Embryonic stem (ES) cells are derived from preimplantation embryos and from cultured primordial germ cells (for reviews, see, Joyner (1993) Gene Targeting, a Practical Approach, Oxford University Press: Oxford; Donovan (1994) Curr. Top. Dev. Biol. 29:189-225).
  • ES cell lines have the remarkable capacity to proliferate in culture without loss of their euploid chromosomal complement and to maintain pluripotency. When they are combined with a preimplantation embryo to form a chimera, ES cells resume normal development and are capable of contributing to all tissues within an organism, including the germ line, (Joyner (1993) supra; Pedersen et al.
  • the human embryo develops from a group of undifferentiated cells into an organism with many specialized cells, tissues, and organs. During embryogenesis, the fates of cells becomes gradually restricted as they enter new developmental pathways. The fate of the inner cell mass (ICM) and trophectoderm has been described for the mouse (Gardner and Papaioannou (1975) in Early Development of Mammals, Cambridge University Press, Cambridge, pp. 107-132) . This study found that the entire fetus and extra-embryonic mesoderm is formed from the non-endoderm cells of the ICM. The ICM of the primate blastocyst contains undifferentiated non-committed cells with the potential to enter a full range of developmental pathways. As these cells differentiate, they lose the capacity to enter developmental pathways that were previously open to them (Anderson (1992) Anim. Biotechnol. 3:165-175) .
  • Embryonic stem cells derived from preimplantation embryos (Martin (1981) Proc. Natl. Acad. Sci. 78:7634-7638; Evans & Kaufman (1981) Nature 292:154-156) and embryonic germ (EG) cells, derived from fetal germ cells (Matsui et al .
  • human and mouse embryos differ in the timing of embryonic genome expression (Braude et al. (1988) Nature 332:459-461), in the structure and function of the fetal membranes and placenta (Benirscheke & Kaufmann (1990) Pathology of the Human Placenta, Springer, New York) , and in formation of an embryonic disc instead of an egg cylinder.
  • EC cells Human embryonal carcinoma (EC) cells, which are pluripotent, immortal stem cells from teratocarcinomas, have been induced to differentiate in culture (Andrews et al. (1984) Lab. Invest. 50:147-162), resulting in loss of specific cell surface markers and the appearance of new markers.
  • the range of differentiation obtained from human EC cell lines is more limited than that obtained from mouse ES cells, and varies widely between cell lines (Pera et al. (1987) Int. J. Cancer 40:334-343) . All pluripotent human EC cell lines derived to date are aneuploid (Roach et al. (1993) Eur. Urol. 23:82-88, suggesting that EC cells do not provide an accurate representation of normal differentiation.
  • Inner cell mass-derived cells were isolated and grown through two passages with the use of a human oviductal epithelial feeder layer in the presence of human leukemia inhibitory factor (LIF) .
  • LIF human leukemia inhibitory factor
  • pluripotent stem cells differentiate into intermediate progenitor cell populations of a variety of cell types, including, hematopoietic, nervous system, muscle, and endodermal cells, through in vitro induction.
  • the present invention describes methods for maintaining primate pluripotent stem cells in culture, and for controlling and directing the differentiation of such cells into a variety of cell types.
  • One aspect of the invention is a method for deriving passagable pluripotent stem cells from early embryos by a) growing an early primate embryo to the blastocyst stage under in vi tro culture conditions in which the developmental potential of pluripotent stem cells is maintained; b) culturing blastocyst stage embryos on feeder cell layers of fibroblasts under conditions wherein cultured pluripotent cells are derived; and c) transferring the derived cells for propagation as secondary cultures.
  • such in vi tro cultures utilize medium containing essential and non-essential amino acids and a defined protein source (which may include transferrin, insulin and LDL) , in the absence of serum.
  • a defined protein source is one of purified human or bovine serum albumin, or purified human or bovine serum non- albumin proteins.
  • An advantage of the invention is the in vi tro production of passagable human pluripotent stem cells derived from early stage embryos, which are useful for the in vi tro production of specifically desired cell types and lineages.
  • Another aspect of this invention is the treatment of a primate by administering cells of the invention to the primate.
  • Another aspect of the invention is an assay which exposes cells of the invention to a compound and determining the effect of the compound on development.
  • An advantage of the invention is that the cells can be maintained in culture for significant periods of time.
  • a feature of the invention is the cell culture medium comprised of a particular combination of ingredients.
  • pluripotent stem cell include multiple pluripotent stem cells.
  • stem cell or “pluripotent stem cell” which terms are used interchangeably, is meant cells that are capable of self-regeneration during propagation, and which have the capacity in vitro or in vivo to differentiate and become intermediate stem cells that further proliferate and terminally differentiate into specific lineages.
  • stem cells refers to cells that have the potential for producing multiple cell types, including for example, hematopoietic, nervous system, muscle, or endodermal cells.
  • embryonic stem cells undifferentiated, immortal cells capable of differentiating into derivatives of all three embryonic germ layers.
  • passagable stem cell or “passagable pluripotent embryonic stem cell” which terms are used interchangeably, is meant stem cells, as described above, that have been propagated in an in vi tro culture for a period of at least about one week, or through 3 or more passages, in an isolated form, i . e . in the absence of blastocyst-derived trophectoderm cells.
  • propagation is meant to cellular reproduction. Generally the phenotype of the cell is maintained through propagation, including its potential for differentiation. The term also includes propagation into cultures where the cells are induced to differentiate into a particular lineage or lineages.
  • embryo By the term “early stage primate embryo” is meant a multi-cellular structure derived by cleavage divisions of the zygote before implantation into the uterus.
  • embryonic germ layer is meant either endoderm, mesoderm, or ectoderm cell layers, which are formed as a result of gastrulation and which interact in the formation of the bodily tissues and organs.
  • blastocyst stage is meant a hollow ball stage embryo with an outer (termed the “trophectoderm”) layer, and an inner group of pluripotent cells (termed the “inner cell mass”) .
  • terminal differentiated cells cells that comprise the predominant cell type of each organ or tissue and have the morphological or biochemical properties that confer a unique identity to each tissue or organ.
  • Cell culture By the term “culturing” or “cell culture” is meant the growth of embryos, cells, or tissue explants outside of the body in a tissue culture environment.
  • Cell culture medium comprises salts and nutrients, e.g. essential and non- essential ammo acids; and generally exogenous proteins, either in the form of defined proteins, e.g. purified human or bovine serum albumin; purified human or bovine serum non- albumin proteins; etc . , or an undefined protein source, e.g. fetal calf serum, human serum, etc.
  • intermediate ste cells stem cells that have a reduced capacity for differentiation relative to pluripotent stem cells, yet still retain the capacity for differentiation into one or more of the cell types contained within a particular tissue or organ.
  • secondary culture is meant the propagation of explanted or derived cells after their initial placement in culture, demonstrating their sustained capacity for cell proliferation. The culture conditions may be the same as those used for the initial derivation, or may be altered to provide for differentiation of the cells.
  • passaging is intended the process of transferring living cells, or colonies derived thereof, sequentially from one culture vessel to another with a concomitant increase in cell number.
  • pluripotent stem cells By the term “derived” or “deriving” pluripotent stem cells is meant establishing the growth of ES cells in cell culture while maintaining their potential for differentiation, including self-regeneration during propagation, and capacity for further differentiation into multiple cell lineages.
  • passagable pluripotent stem cells are derived in the absence of growth factors that induce differentiation, and in the presence of growth factors that maintain the cells in an undifferentiated state by restraining differentiation.
  • controlling and “directing" differentiation of pluripotent stem cells is meant directing the differentiation of pluripotent stem cells into specifically desired cell lineages through the control of culture conditions, including supplementing and depleting culture medium of specific growth factors.
  • growth factor is meant a molecule capable of promoting growth or differentiation of cells, either in culture or in the intact tissue, through its specific effects on a transmembrane receptor.
  • Growth factors include polypeptides, such as fibroblast growth factor, and non-polypeptide factors such as retinoic acid, that also specifically influence the growth and differentiation of cells through their action on intracellular receptor molecules that specifically mediate growth-promoting or differentiative effects.
  • Epidermal growth factor(s) is meant a factor that acts through an epidermal growth factor receptor.
  • EGF receptors include EGF-R (HER-1), HER-2, HER-3, and HER-4.
  • EGFs include epidermal growth factor, transforming growth factor ⁇ , heparin-binding epidermal growth factor, amphiregulin, heregulins, epiregulin, ⁇ -cellulin and cripto.
  • fibroblast growth factor(s) is meant a factor known to act through a fibroblast growth factor receptor.
  • Known FGF receptors include FGFR1, FGFR2 (including KGFR) , FGFR3, and FGFR4.
  • Known FGFs include FGF-1 (acidic FGF), FGF-2 (basic FGF), FGF-3, FGF-4, FGF-5, FGF-6, FGF-7 (keratinocyte growth factor), FGF-8 (androgen-induced growth factor) , and FGF-9 (glial activating growth factor) .
  • inhibitor of the function of specific growth factor or receptor is meant an agent that interferes with the biological function of a growth factor, either by interacting with the factor itself, with its receptor, or by interfering with the function of other molecules that transduce the effects of growth factor-receptor interaction.
  • inducing or “induction” of differentiation is meant causing the differentiation of cultured cells through certain additions, depletions, or other modifications of their environment, so as to bring about directed changes in the morphological or biochemical properties of the cells.
  • treatment means obtaining a desired pharmacologic and/or physiologic effect.
  • the effect may be prophylactic in terms of completely or partially preventing a disease or symptom thereof and/or may be therapeutic in terms of a partial or complete cure for a disease and/or adverse effect attributable to the disease.
  • Treatment covers any treatment of a disease in a mammal, particularly a human, and includes:
  • Passagable primate pluripotential embryonic stem cells are derived and propagated in in vi tro culture. Methods are also provided for controlling the differentiation pathway of the passagable pluripotent stem cells to produce cells of a specifically desired type. These cells thus have significant clinical use in transplantation therapy for genetic disease, cancer, and other degenerative conditions, such as amyotrophic lateral sclerosis, Huntington's disease, Parkinson's disease,Alzheimer ' s disease, etc.
  • primate pluripotent stem cells inculding human pluripotent stem cells
  • the derived cells may be passaged as secondary cultures for propagation of the pluripotent cells, or to induce differentiation wherein intermediate stem cells or terminally differentiated, tissue-specific cells are generated.
  • Components of the in vitro culture medium including nutrients, feeder layer cells, growth factors and protein source, are manipulated in order to achieve the maintenance of pluripotential capacity, or to drive the cells into differentiation.
  • the culture medium and conditions are selected to optimize viability at each stage of the invention.
  • the source of pluripotent stem cells is the inner cell mass of a primate blastocyst stage embryo.
  • Primate species of interest include humans; apes, e.g. chimpanzees, gorillas, orangutans and bonobos; old world and new world monkeys, e.g. macaques, baboons, etc . ; and prosimians.
  • human embryos are obtained by donation with informed consent from patients, e.g. undergoing m vitro fertilization as therapy for infertility. Such donations adhere to protocols for human embryo research as approved by the responsible Institutional Review Board(s) .
  • the blastocysts may be grown in culture prior to isolation of the inner cell mass, or cells may be directly isolated from an m vivo derived blastocyst.
  • the medium comprises simple components. Suitable medium includes Earles' medium; Hank's balanced salt solution (HBSS) ; Eagle medium,
  • the medium will include essential ammo acids, at a concentration ranging from about 0.5X to 5x the standard concentration, i.e. that which is typically found in medium such as Dulbecco' s modified Eagle medium (DME) . Non-essential ammo acids are also included, at a comparable concentration.
  • the initial medium will further comprise a protein source, such Synthetic Serum Substitute (Irvine Scientific Co., Irvine, CA) ; purified human or bovine serum albumin; purified human or bovine serum non- albumin proteins, e.g. LDL, transferrin, insulin, etc .
  • the medium is not supplemented with a complex source of protein, i.e.
  • Culture environmental components include extracellular matrix components, e.g. fibronectin, vitronectin, laminin, collagen type IV or Matrigel; low oxygen tension ( ⁇ 20%); antibiotics; and reducing agents, e.g. b-mercaptoethanol, monothioglycerol, etc.
  • Pluripotent inner cell mass cells are isolated from the trophectoderm by culture outgrowth, or by selective lysis of the trophectoderm.
  • the trophectoderm cells are destroyed, leaving the inner cell mass.
  • the trophectoderm may be coated with a molecular layer of trinitrobenzene sulfonic acid, washing, treating with an antibody to its derivative, DNP, and then treating with active serum complement.
  • the immunosurgery may also be accomplished by coating the trophectoderm with anti- species antibody (i.e. anti-human, anti-gorilla, etc . ) followed by washing and treatment with active serum complement.
  • lysis is accomplished by brief treatment with a Ca ++ ionophore, e.g. A23187 at a concentration of 1-5 x 10 "5 M, to lyse the outer cells.
  • Ca ++ ionophore e.g. A23187 at a concentration of 1-5 x 10 "5 M
  • These processes release the inner cell mass, which is then cultured as isolated cells on a feeder cell layer, as described below.
  • the intact cleavage stage embryo is placed on the feeder cell layer and allowed to attach, flatten and grow as a two-dimensional structure containing the pluripotent cells at the center of the outgrowth.
  • the pluripotent cells are isolated by physical separation, e.g. by micropipet.
  • the culture conditions for blastocysts and isolated inner cell mass cells are the same unless otherwise specified, herein termed "derivation medium”.
  • the derivation medium comprises a complex culture medium, e.g. Dulbecco' s modified eagle medium (DME) ; RPMI; Iscove's modified Dulbecco' s medium (IMDM); etc. ; supplemented with non-essential amino acids and environmental culture conditions as previously described. It is not necessary to supplement with essential amino acids, which are already present in the medium formulation.
  • a feeder layer is used.
  • a number of different cells can be used as a feeder layer, e.g. fibroblasts derived human oviductal epithelium; fetal fibroblasts derived by primary culture from the same species as the embryo; buffalo rat liver cells (BRL) cells; etc .
  • fibroblasts derived human oviductal epithelium fetal fibroblasts derived by primary culture from the same species as the embryo
  • buffalo rat liver cells (BRL) cells etc .
  • These cell layers provide non-defined components to the medium and restrain the differentiation of the pluri
  • the derivation medium is deficient in differentiative growth factors, i.e. those that induce differentiation in embryonic stem cells, e.g. epidermal growth factor; fibroblast growth factor (s) and include factors known to act through an epidermal growth factor receptor, including the EGF-R (HER-1) and HER-2, HER-3, and HER-4, and/or a fibroblast growth factor receptor, including FGFR1, FGFR2 (KGFR) , FGFR3, and FGFR .
  • serum-free medium is used, supplemented with defined, purified proteins, e.g. transferrin; albumin; insulin; etc . where the growth factors are absent ab initio from the medium.
  • the differentiative growth factors may also be present in the medium, but blocked from exerting their biological activity through the addition of blocking agents, e.g. antibodies that interfere with the binding of the factors and their cognate receptor; or alternatively with tyrphostins that specifically interrupt the signal transduction cascade mediated by epidermal growth factor receptor, thus impairing the effect of the several growth factors that act through the EGF receptor, etc.
  • the blastocyst culture medium further comprises at least one maintenance growth factor, i . e . factors that stimulate the growth of stem cells while maintaining their potential for differentiation.
  • a cocktail comprising two or more maintenance growth factors may also be used.
  • LIF leukemia inhibitory factor
  • CSF-1 colony stimulating factor-1
  • c-kit ligand steel factor
  • CNTF ciliary neurotrophic factor
  • the inner cell mass expands into a small cluster of pluripotent cells and their differentiated derivatives.
  • These passagable pluripotent stem cells are isolated mechanically, dissociated slightly, e.g. in trypsin, EDTA, dispase collagenase, etc., and transferred to fresh feeder layers for further culture, using the conditions described for derivation medium.
  • trypsin is used for passaging the cells
  • the medium may be modified to include trypsin inhibitors, e.g. peptide substrates, serum, soybean trypsin inhibitor, etc.
  • the passagable pluripotent embryonic stem cells thus derived have a number of uses, including differentiation into multiple cell lineages, drug screening, as a model for differentiation, etc .
  • the subsequent differentiation into intermediate stem cells or terminally differentiated cells is achieved through exposure to differentiative growth factors, including erythropoiet , bone morphogenetic protem(s), epidermal growth factor(s), and fibroblast growth factor(s), and to culture environmental components including the extracellular matrix components fibronect , vitronect , laminin, and collagen type IV, low oxygen tension ( ⁇ 20° o ), and reducing agents.
  • concentration of each supplemented factor or component will depend on the specific factor or component, and may be readily determined by one skilled in the art.
  • fibroblast growth factor(s) is supplied in a concentration range of approximately 10-100 ng/ml.
  • Such cultures may utilize medium that is depleted in stem cell maintenance growth factors, including human LIF, CNTF, CSF-1, steel factor, etc .
  • the intermediate stem cells of the invention find use as therapeutic agents by transplantation to regenerate lineages of a host deficient in stem cells.
  • Conditions where such therapy is used include rescuing a subject that is diseased, e.g. suffering from lymphoma, leukemia, or other neoplastic condition, and can be treated by removal or destruction of bone marrow and hematopoietic tissue by irradiation or chemotherapy, followed by engraftment with the cells of the invention.
  • the cells of the invention may be used for the treatment of genetic diseases, by restoring genetic function in genetically modified somatic cells.
  • diseases including, but not limited to, ⁇ -thalassemia, sickle cell anemia, adenosine deaminase deficiency, recombinase deficiency, recombinase regulatory gene deficiency, etc. may be corrected by introduction of a wild-type gene into the cells of the invention, either by homologous or random recombination.
  • Other indications of gene therapy are introduction of drug resistance genes to enable the cells of the invention to have an advantage and be subject to selective pressure during chemotherapy. Suitable drug resistance genes include, but are not limited to, the gene encoding the multidrug resistance (MDR) protein.
  • MDR multidrug resistance
  • Diseases other than those associated with hematopoietic cells may also be treated, where the disease is related to the lack of a particular secreted product including, but not limited to, hormones, enzymes, interferon, growth factors, or the like.
  • a particular secreted product including, but not limited to, hormones, enzymes, interferon, growth factors, or the like.
  • inducible production of the deficient protein may be achieved, so that production of the protein will parallel natural production, even though production will be in a different cell type from the cell type that normally produces such protein. It is also possible to insert a ribozyme, antisense or other message to inhibit particular gene products or susceptibility to diseases.
  • the passagable pluripotent stem cells may be frozen at liquid nitrogen temperatures and stored for long periods of time, being thawed and capable of being reused.
  • the cells will usually be stored in 5% DMSO and 95% fetal calf serum.
  • Once thawed, the cells may be expanded by use of growth factors or stromal cells associated with stem cell proliferation and differentiation.
  • the cells may optionally be modified to have at least one non-autologous gene, as described above for use in gene therapy, and such genetically altered populations and their progeny are embraced within the scope of this invention.
  • compositions comprising the cells of the invention a form suitable for administration, e.g. by injection or infusion, to a patient in need thereof, m combination with a suitable carrier medium for use in any of the foregoing treatments.
  • a suitable carrier medium for use in any of the foregoing treatments.
  • Dosages of the cells of the invention for pharmaceutical uses such as reconstitution of the hematopoietic system of a patient in need thereof, will vary depending on the nature of the condition to be treated and the other aspects of the patient's treatment, e.g. prior radiation or chemotherapy, or co-therapy with agents having an influence on hematopoiesis, e.g. cytok es, as well as on the purity and viability of the cell population to be administered.
  • the cells of the invention are also of use as research tools in producing various lineage restricted cell lines; detecting and evaluating growth factors relevant to stem cell self-regeneration; assaying for factors associated with development; and to test drugs that modulate or affect such systems and treat or alleviate such diseases as Parkinson' s disease; to replace tissue destroyed by degenerative or autoimmune disease; e.g. b-islet cells; identifying support cells (endothelial, stromal, fibroblast) in the developing embryo that allow for growth and differentiation of various lineages, etc .
  • the stem cells of the invention may be used m assays to determine either autocnne or parac ⁇ ne regulatory signals and evaluate responses to growth factor either from external or intrinsic protein sources; and to determine the activity of media, such as conditioned media, evaluate fluids for cell growth activity, involvement with differentiation into particular lineages, or the like.
  • Stem cell factors may be isolated from media or cell extracts of supportive cells in which a population of the cells of the invention are growing or a supernate of a population of the cells, by separating or fractionating the fluid, e.g. chromatographically.
  • the active fraction containing the desired factor is identified by measuring the growth and differentiation of stem cells in the presence and absence of such fractions, or alternatively, using comparative analysis of fluid obtained from a population of stem cells.
  • cDNA libraries of the cells of the invention may be prepared and screened for genes encoding factors of interest. Growth factor or receptor genes in the cDNA libraries may optionally be amplified and identified using oligonucleotide primers based on conserved sequences within known growth factor or receptor families.
  • Immortalized cells of the invention are useful as being cells that are responsive to a factor allowing for the regeneration of stem cells, e.g. in assays for survival, activation, or proliferation in the presence and absence of the putative stem cell growth or maintenance factor.
  • EXAMPLES The following examples are put forth so as to provide those of ordinary skill in the art with a complete disclosure and description of how to establish human pluripotent stem cell lines and their induced differentiation, and are not intended to limit the scope of what the inventors regard as their invention. Unless indicated otherwise, parts are parts by weight, temperature is in degrees centigrade, and pressure is at or near atmospheric pressure. Efforts have been made to ensure accuracy with respect to numbers used (e.g., molecular weights, amounts, particular components, etc.), but some deviations may exist.
  • Example 1 Establishment of Human Pluripotent Stem Cell Lines Pre-blastocvst culture conditions. Generally, embryos fertilized in vitro or retrieved from the reproductive tract at early cleavage stages are cultured to the blastocyst stage at 37°c in an atmosphere of 5% CO ? , 95% air, in a simple medium such as KSOM (See Lawitts and Biggars (1993) Meth. in Enzvm. 225:153-164) supplemented with a protein source, such as KSOM (See Lawitts and Biggars (1993) Meth. in Enzvm. 225:153-164) supplemented with a protein source, such
  • Synthetic Serum Substitute (Irvine Scientific Co., Irvine, CA) , purified human or bovine serum albumin protein, purified human or bovine serum non-albumin proteins (including transferrin, LDL, insulin, etc. ) , and with essential amino acids at 0.5x-5x their concentration in Dulbecco's modified Eagles medium (DME), and non-essential amino acids at comparable concentrations (see Ho et al . (1995) Mol. Rep, and Develop. 41:232-238) .
  • DME Dulbecco's modified Eagles medium
  • the protein source is provided for ease of handling and the amino acids are provided as a fixed nitrogen source. Blastocyst culture conditions. When embryos reach the blastocyst stage (or at the eight cell stage for human embryos, in the event that they are available before the blastocyst stage) , they are transferred to a complex medium, such as DME.
  • DME is supplemented with non-essential amino acids, 3-mercaptoethanol or monothioglycerol, nucleosides, and antibiotics as previously described (Robertson (1987) in Teratocarcmomas and Embryonic Stem Cells: A Practical Aproach, Oxford University Press, Oxford, UK, pp. 71-112) . Additional supplements include the growth factors described below under “Growth factors added during derivation and propagation of pluripotent stem cells.”
  • Fibroblasts or fibroblast-like cells grown as monolayers, are instrumental in the derivation of pluripotent primate cells. Fibroblasts from a variety of sources can be used for this purpose, for example, mouse fetal or human fetal fibroblasts, or human oviductal epithelium cells.
  • the feeder cells are inactivated by irradiation with 5-6,000 rads, 250 kVp, or treatment with 0.01 mg/ml mitomycin C for 3.5 h at 37oC; then they are plated, washed, and grown to confluency on gelatin or extracellular matrix-coated dishes (as described below) . The feeder layers are then used for growing the early stage embryos or secondary stem cell cultures.
  • the following polypeptide growth factors are added as supplements to the DME medium during pluripotent stem cell derivation and propagation to maintain the pluripotent, undifferentiated state of the stem cells which would otherwise differentiate in their absence.
  • the cytok es leukemia inhibitory factor (LIF) and ciliary neurotrophic factor (CNTF) are used at 100-10,000 U/ml.
  • the cytokine macrophage colony stimulating factor 1 (CSF-1) is used to sustain the proliferation of the pluripotent stem cells and is present at a concentration of between 100-1000 U/ml.
  • growth factors are oncostatin M at a concentration of from 2 to 200 ng/ml, usually about 20 ng/ l; and IL6 at a concentration of from 50 to 5000 ng/ml, usually 500 ng/ml; IL6 soluble receptor at a concentration of from 1 to 10 mg/ml, usually 5 mg/ml.
  • Other factors in stem cell derivation The key novel aspect of deriving pluripotent cells from early stage primate embryos lies in restraining their spontaneous differentiation into the early lineages and embryonic germ layers during post- blastocyst culture. This is accomplished by a combination of biophysical, biochemical, and biological conditions.
  • Biophysical conditions The effects of oxidative damage on the survival of pluripotent cells is restrained by maintaining cells at below ambient oxygen levels (20%), achieved by mixing nitrogen with air to achieve the necessary lower 0 ? levels (5-10%) .
  • small amounts of a reducing agent are consistently maintained in the culture medium ( ⁇ -mercaptoethanol, 0.2-1.0 ppm (v/v) ; monothioglyceral) .
  • the substrata on which pluripotent cells are cultured have a role in deterring differentiation of pluripotent cells. Accordingly, during derivation of pluripotent stem cells from early stage embryos, the embryos and secondary cultures are maintained on extracellular matrices, either those produced by the feeder cell layers (see below), gelatin, or purified matrix components, such as fibronectin, vitronectin, laminin, and/or collagen type IV, or MATRIGELTM (Collaborative Research, Inc.) In the latter instance, culture dishes are coated with extracellular matrix component (s) by placing a solution (20-40 ⁇ g/ml) in the dish for 2 h, then washing the dishes with saline before adding culture medium, and embryos or cells to the dishes.
  • extracellular matrix component s
  • Feeder layer-derived extracellular matrices are generated by culturing non-inactivated fibroblasts to confluency on dishes, then lysing the cells with Triton X-100 (0.5% v/v), and washing extensively with saline. Growth factor depletion strategies. Key to propagating primate pluripotent cells in an undifferentiated state is to deplete the growth medium of factors that induce their differentiation into intermediate stem cells or terminally-differentiated cells. In a preferred embodiment, serum-free medium is used to achieve essentially complete absence of differentiative growth factors.
  • serum may be depleted of differentiation inducing substances.
  • epidermal growth factor (s) and/or fibroblast growth factor (s) are depleted from the serum used in the derivation of pluripotent cells from early stage embryos. This is accomplished either by using a defined protein source (Synthetic Serum Substitute, Irvine Scientific Co.), by selecting serum types and specific lots low in these factors, or by extracting the specific growth factor from the serum.
  • fibroblast growth factors are removed from serum by stirring DME medium containing 20% serum overnight in the presence of an equal volume of heparin-derivatized Sephadex beads, which bind fibroblast growth factors and remove them from the medium.
  • the depletion step is repeated until the growth factor (s) are present at below threshhold levels for inducing stem cell differentiation.
  • removal is accomplished by derivatizing Sephadex beads with an antibody to the growth factor, mixing beads with serum-containing medium, and repeating this treatment until the differentiation-stimulating activity is removed from the serum.
  • the growth factor-depleted serum may be replaced with complete serum, e.g. 10% heat-inactivated fetal bovine serum and 10% heat-inactivated newborn calf serum, which have been quality control tested for the capacity to support the secondary culture of established embryonic stem cells. Functional deprivation strategies.
  • An alternative to depleting the growth medium of differentiation-stimulating growth factors is to functionally interfere or perturb the activity of the growth factors.
  • a specific function- perturbing antibody is available, the action of specific growth factors is inhibited by adding the function-perturbing antibody directly to the serum-containing medium to inactivate the factor.
  • a growth factor receptor function- perturbing antibody is available, the antibody is added to the medium, thereby blocking the function of the specific growth factor receptor.
  • epidermal growth factor receptor (EGF-R) transduction is interrupted by treating the cells with certain tyrphostins that are EGF-R selective tyrosine kinase inhibitors.
  • EGF-R epidermal growth factor receptor
  • the action of FGF signalling receptors is inhibited at specific steps of the Ras/mitogen-activated protein (MAP) kinase pathway.
  • MAP Ras/mitogen-activated protein
  • Feeder cell layers are prepared as described above and used as an adjunct to the defined factors that support derivation and secondary culture of pluripotent stem cells. Regarding the role of the feeder cell layers, no rigorous distinction can be made between provisions of undefined growth factors to the medium, or removal by exhaustion or adsorption of growth factors that would otherwise induce differentiation of the stem cells.
  • the general method for inducing the differentiation of established pluripotent stem cells into intermediate stem cells and subsequently into terminally differentiated cells s related to the derivation strategy in that it relies on a deprivation/supplementation regimen involving specific polypeptide growth factors.
  • To induce differentiation of the pluripotent stem cells it is first necessary to release the inhibition conferred by maintenance growth factors such as LIF, CNTF, etc. This is accomplished by omitting the maintenance growth factors from the culture medium. Simultaneously, exposure to one or more, but not all, polypeptide growth factors is used to induce the specific differentiation of intermediate stem cells.
  • fibroblast growth factor (10-100 ng/ml) is added to induce the differentiation of mesoderm and its derivatives, such as muscle.
  • Other growth factors are omitted or specifically depleted to achieve specificity of differentiation, and thus prevent induction of undesired productions (e.g., induction of the myeloid pathway by CSF-1) .
  • the methods for achieving the depletions and/or functional deprivations are the same as those described above.
  • Example 2 Pluripotent stem cell culture in serum-free medium.
  • Murine pre-implantation embryos were tested for the outgrowth of ES cell lines, i.e. cell lines that show the same morphology and proliferation rate as ES cell lines with demonstrated germ-line capacity.
  • Blastocysts were grown in Knockout-DMEMTM containing ES cell supplement serum replacement (Life technologies R&D, Grand Island, NY) . The results are shown in Table 1.
  • Human pre-implantation embryos were grown in Earle's medium supplemented with essential and non-essential amino acids and with synthetic serum supplement. The embryos were then moved onto KSOM with BRL cell feeder layers supplemented with essential and non-essential amino acids and with synthetic serum supplement. After 5 to 7 days total growth past-fertilization, the blastocyst stage embryos were transferred to two different culture conditions.
  • the serum-free cultures contained mouse fibroblast feeder layer cells, DME, 25 mM sodium bicarbonate, IX non- essential amino acids, 2% bovine serum albumin, 200 mg/ml transferrin, 10 mg/ml insulin, 20 mg/ml LDL, 1% penicillin/streptomycin and 7.5 x 10 "5 monothioglycerol . As maintenance growth factors, both LIF (100 U/ml) and oncostatin M (22 ng/ml) were added to the medium.
  • the serum containing cultures contained DME with 10% fetal calf serum and 10% newborn calf serum and LIF at 100 U/ml. Cultures were evaluated after 5-7 days. The results are shown in Table 2, where outgrowths are defined as a blastocyst that has attached and spread in two dimensions to a feeder layer of cells and is showing cell proliferation.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Gynecology & Obstetrics (AREA)
  • Biotechnology (AREA)
  • Reproductive Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Developmental Biology & Embryology (AREA)
  • Organic Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

Cette invention concerne des procédés de différenciation et de prolifération de cellules souches multipotentes transférables provenant d'embryons précoces de primates. Les cellules souches multipotentes transférables, lorsqu'elles sont placées dans des conditions de culture in vitro modifiées, peuvent se différencier en une multitude de types de cellules souches intermédiaires. En tant que telles, elles sont utiles comme modèles pour une mise au point précoce, pour le traitement d'une variété de maladies génétiques ou dégénérescences et pour la fabrication de composées de dosage permettant d'établir leur effet en matière de mise au point.
PCT/US1997/010316 1996-06-14 1997-06-13 Differenciation et culture in vitro de cellules souches multipotentes de primates et usages therapeutiques WO1997047734A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU33926/97A AU3392697A (en) 1996-06-14 1997-06-13 (in vitro) derivation and culture of primate pluripotent stem cells and therapeutic uses thereof

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US66521796A 1996-06-14 1996-06-14
US08/665,217 1996-06-14

Publications (1)

Publication Number Publication Date
WO1997047734A1 true WO1997047734A1 (fr) 1997-12-18

Family

ID=24669212

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1997/010316 WO1997047734A1 (fr) 1996-06-14 1997-06-13 Differenciation et culture in vitro de cellules souches multipotentes de primates et usages therapeutiques

Country Status (2)

Country Link
AU (1) AU3392697A (fr)
WO (1) WO1997047734A1 (fr)

Cited By (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000034525A1 (fr) * 1998-12-09 2000-06-15 Vistagen, Inc. Typage de toxicite utilisant des corps embryoides
US6271436B1 (en) 1996-10-11 2001-08-07 The Texas A & M University System Cells and methods for the generation of transgenic pigs
US6506574B1 (en) * 2000-04-27 2003-01-14 Geron Corporation Hepatocyte lineage cells derived from pluripotent stem cells
JP2003525625A (ja) * 2000-03-09 2003-09-02 ウィスコンシン アラムニ リサーチ ファンデーション 霊長類の胚幹細胞の無血清培養
US6635802B1 (en) 2000-01-10 2003-10-21 The Texas A&M University System Nuclear transfer using cells cultured in serum starvation media containing apoptosis inhibitors
US6642048B2 (en) 2000-01-11 2003-11-04 Geron Corporation Conditioned media for propagating human pluripotent stem cells
US6887706B2 (en) 2001-10-03 2005-05-03 Wisconsin Alumni Research Foundation Method of in vitro differentiation of transplantable neural precursor cells from primate embryonic stem cells
US7148062B2 (en) 2002-03-15 2006-12-12 Wicell Research Institute, Inc. Method for generating primate trophoblasts
US7176023B2 (en) 2001-11-02 2007-02-13 Wisconsin Alumni Research Foundation Endothelial cells derived from primate embryonic stem cells
US7297539B2 (en) 2000-01-11 2007-11-20 Geron Corporation Medium for growing human embryonic stem cells
WO2008049161A1 (fr) * 2006-10-24 2008-05-02 Adelaide Research & Innovation Pty Ltd Procédé destiné à isoler des cellules pluripotentes à partir d'un embryon pré-implantatoire dans un milieu de culture exempt de sérum animal
US7439064B2 (en) 2000-03-09 2008-10-21 Wicell Research Institute, Inc. Cultivation of human embryonic stem cells in the absence of feeder cells or without conditioned medium
US7455983B2 (en) 2000-01-11 2008-11-25 Geron Corporation Medium for growing human embryonic stem cells
US7473555B2 (en) 2000-04-27 2009-01-06 Geron Corporation Protocols for making hepatocytes from embryonic stem cells
US7588937B2 (en) 2001-10-03 2009-09-15 Wisconsin Alumni Research Foundation Method of in vitro differentiation of neural stem cells, motor neurons and dopamine neurons from primate embryonic stem cells
US8143009B2 (en) 2000-06-14 2012-03-27 Vistagen, Inc. Toxicity typing using liver stem cells
US8148151B2 (en) 2006-06-02 2012-04-03 Geron Corporation Differentiation of primate pluripotent cells to hepatocyte-lineage cells
US8153424B2 (en) 2001-10-03 2012-04-10 Wisconsin Alumni Research Foundation Method of in vitro differentiation of neural stem cells, motor neurons and dopamine neurons from primate embryonic stem cells
US9074181B2 (en) 2005-06-22 2015-07-07 Asterias Biotherapeutics, Inc. Suspension culture of human embryonic stem cells

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1990001541A1 (fr) * 1988-08-04 1990-02-22 Amrad Corporation Limited Propagation in vitro de cellules a tiges embryonnaires
WO1995012665A1 (fr) * 1993-11-03 1995-05-11 Diacrin, Inc. Cellules souches embryonnaires capables de se differencier en lignees cellulaires desirees
WO1995016770A1 (fr) * 1993-12-17 1995-06-22 Abs Global, Inc. Cellules souches embryonnaires derivees de cellules du stade preblastocyste d'ongule et leur utilisation pour produire des ongules chimeres et transgeniques clones
US5453357A (en) * 1992-10-08 1995-09-26 Vanderbilt University Pluripotential embryonic stem cells and methods of making same
WO1996022362A1 (fr) * 1995-01-20 1996-07-25 Wisconsin Alumni Research Foundation Cellules souches embryonnaires de primates

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1990001541A1 (fr) * 1988-08-04 1990-02-22 Amrad Corporation Limited Propagation in vitro de cellules a tiges embryonnaires
US5453357A (en) * 1992-10-08 1995-09-26 Vanderbilt University Pluripotential embryonic stem cells and methods of making same
WO1995012665A1 (fr) * 1993-11-03 1995-05-11 Diacrin, Inc. Cellules souches embryonnaires capables de se differencier en lignees cellulaires desirees
WO1995016770A1 (fr) * 1993-12-17 1995-06-22 Abs Global, Inc. Cellules souches embryonnaires derivees de cellules du stade preblastocyste d'ongule et leur utilisation pour produire des ongules chimeres et transgeniques clones
WO1996022362A1 (fr) * 1995-01-20 1996-07-25 Wisconsin Alumni Research Foundation Cellules souches embryonnaires de primates

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
BONGSO A ET AL: "ISOLATION AND CULTURE OF INNER CELL MASS CELLS FROM HUMAN BLASTOCYSTS", HUMAN REPRODUCTION, vol. 9, no. 11, 1994, OXFORD GB, pages 2110 - 2117, XP000613489 *
NICHOLS J ET AL: "DERIVATION OF GERMLINE COMPETENT EMBRYONIC STEM CELLS WITH A COMBINATION OF INTERLEUKIN-6 AND SOLUBLE INTERLEUKIN-6 RECEPTOR", EXPERIMENTAL CELL RESEARCH, vol. 215, no. 1, November 1994 (1994-11-01), US, pages 237 - 239, XP002044063 *
THOMSON J A ET AL: "ISOLATION OF A PRIMATE EMBRYONIC STEM CELL LINE", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF USA., vol. 92, no. 17, August 1995 (1995-08-01), WASHINGTON US, pages 7844 - 7848, XP000604992 *

Cited By (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6369294B1 (en) 1996-10-11 2002-04-09 Texas A&M University System Methods comprising apoptosis inhibitors for the generation of transgenic pigs
US6271436B1 (en) 1996-10-11 2001-08-07 The Texas A & M University System Cells and methods for the generation of transgenic pigs
US8097458B2 (en) 1998-10-23 2012-01-17 Geron Corporation Micro-carrier culture system for rapid expansion of human embryonic stem cells
US8951800B2 (en) 1998-10-23 2015-02-10 Asterias Biotherapeutics, Inc. Primate pluripotent stem cell expansion without feeder cells and in the presence of FGF and matrigel or Engelbreth-Holm-Swarm tumor cell preparation
US10059939B2 (en) 1998-10-23 2018-08-28 Asterias Biotherapeutics, Inc. Screening methods for human embryonic stem cells
US8637311B2 (en) 1998-10-23 2014-01-28 Asterias Biotherapeutics, Inc. Human embryonic stem cells genetically modified to contain a nucleic acid and cultured with fibroblast growth factor
WO2000034525A1 (fr) * 1998-12-09 2000-06-15 Vistagen, Inc. Typage de toxicite utilisant des corps embryoides
US6635802B1 (en) 2000-01-10 2003-10-21 The Texas A&M University System Nuclear transfer using cells cultured in serum starvation media containing apoptosis inhibitors
US7297539B2 (en) 2000-01-11 2007-11-20 Geron Corporation Medium for growing human embryonic stem cells
US7455983B2 (en) 2000-01-11 2008-11-25 Geron Corporation Medium for growing human embryonic stem cells
US6642048B2 (en) 2000-01-11 2003-11-04 Geron Corporation Conditioned media for propagating human pluripotent stem cells
US6667176B1 (en) 2000-01-11 2003-12-23 Geron Corporation cDNA libraries reflecting gene expression during growth and differentiation of human pluripotent stem cells
US7041438B2 (en) 2000-01-11 2006-05-09 Geron Corporation Use of human embryonic stem cells for drug screening and toxicity testing
US7005252B1 (en) 2000-03-09 2006-02-28 Wisconsin Alumni Research Foundation Serum free cultivation of primate embryonic stem cells
US7439064B2 (en) 2000-03-09 2008-10-21 Wicell Research Institute, Inc. Cultivation of human embryonic stem cells in the absence of feeder cells or without conditioned medium
JP2003525625A (ja) * 2000-03-09 2003-09-02 ウィスコンシン アラムニ リサーチ ファンデーション 霊長類の胚幹細胞の無血清培養
US7473555B2 (en) 2000-04-27 2009-01-06 Geron Corporation Protocols for making hepatocytes from embryonic stem cells
US6506574B1 (en) * 2000-04-27 2003-01-14 Geron Corporation Hepatocyte lineage cells derived from pluripotent stem cells
US9587223B2 (en) 2000-04-27 2017-03-07 Asterias Biotherapeutics, Inc. Protocols for making hepatocytes from embryonic stem cells
EP2256187A1 (fr) 2000-04-27 2010-12-01 Geron Corporation Cellules hépatocytes de lignée derivées de cellules souches pluripotentielles
US8546139B2 (en) 2000-04-27 2013-10-01 Geron Corporation Protocols for making hepatocytes from embryonic stem cells
US8512957B2 (en) 2000-06-14 2013-08-20 Vistagen Therapeutics, Inc. Toxicity typing using liver stem cells
US8143009B2 (en) 2000-06-14 2012-03-27 Vistagen, Inc. Toxicity typing using liver stem cells
US7410798B2 (en) 2001-01-10 2008-08-12 Geron Corporation Culture system for rapid expansion of human embryonic stem cells
US9080151B2 (en) 2001-10-03 2015-07-14 Wisconsin Alumni Research Foundation Method of in vitro differentiation of neural stem cells, motor neurons and dopamine neurons from primate embryonic stem cells
US6887706B2 (en) 2001-10-03 2005-05-03 Wisconsin Alumni Research Foundation Method of in vitro differentiation of transplantable neural precursor cells from primate embryonic stem cells
US7588937B2 (en) 2001-10-03 2009-09-15 Wisconsin Alumni Research Foundation Method of in vitro differentiation of neural stem cells, motor neurons and dopamine neurons from primate embryonic stem cells
US8153424B2 (en) 2001-10-03 2012-04-10 Wisconsin Alumni Research Foundation Method of in vitro differentiation of neural stem cells, motor neurons and dopamine neurons from primate embryonic stem cells
US7972850B2 (en) 2001-10-03 2011-07-05 Wisonsin Alumni Research Foundation Method of in vitro differentiation of neural stem cells, motor neurons and dopamine neurons from primate embryonic stem cells
US7176023B2 (en) 2001-11-02 2007-02-13 Wisconsin Alumni Research Foundation Endothelial cells derived from primate embryonic stem cells
US7148062B2 (en) 2002-03-15 2006-12-12 Wicell Research Institute, Inc. Method for generating primate trophoblasts
US10435666B2 (en) 2002-03-15 2019-10-08 Wicell Research Institute, Inc. Method for generating primate trophoblasts
US9074181B2 (en) 2005-06-22 2015-07-07 Asterias Biotherapeutics, Inc. Suspension culture of human embryonic stem cells
US10676714B2 (en) 2005-06-22 2020-06-09 Asterias Biotherapeutics, Inc. Suspension culture of human embryonic stem cells
US8148151B2 (en) 2006-06-02 2012-04-03 Geron Corporation Differentiation of primate pluripotent cells to hepatocyte-lineage cells
AU2007308746B2 (en) * 2006-10-24 2014-05-08 Icmstemcell Pty Ltd Method for the isolation of pluripotent cells from a pre-implantation embryo in a culture medium free from animal serum
US9499785B2 (en) 2006-10-24 2016-11-22 Icmstemcell Pty Ltd Isolating a mammalian embryonic stem cell from a homogenous pluripotent outgrowth of a mammalian pre-implantation embryo
WO2008049161A1 (fr) * 2006-10-24 2008-05-02 Adelaide Research & Innovation Pty Ltd Procédé destiné à isoler des cellules pluripotentes à partir d'un embryon pré-implantatoire dans un milieu de culture exempt de sérum animal

Also Published As

Publication number Publication date
AU3392697A (en) 1998-01-07

Similar Documents

Publication Publication Date Title
US11512283B2 (en) Media for culturing stem cells
US10351821B2 (en) Neural cell populations from primate pluripotent stem cells
WO1997047734A1 (fr) Differenciation et culture in vitro de cellules souches multipotentes de primates et usages therapeutiques
US7297539B2 (en) Medium for growing human embryonic stem cells
US20090311781A1 (en) Methods of expanding embryonic stem ceels in a suspension culture
CA2434362A1 (fr) Cellules souches adultes pluripotentes provenant de tissu regeneratif
WO2005017131A2 (fr) Methodes pour la differenciation de cellules souches humaines
US20080260722A1 (en) Method for High Efficiency Survival/Proliferation of Human Embyonic Stem Cells and Human Embryo Survival in Culture
Fang et al. Stem cells and combinatorial science
AU2012261726B2 (en) Media for Culturing Stem Cells
Schuldiner et al. differentiation of human
AU2015203310A1 (en) Media for Culturing Stem Cells
AU2002244652A1 (en) Pluripotent adult stem cells derived from regenerative tissue

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE HU IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK TJ TM TR TT UA UG UZ VN YU AM AZ BY KG KZ MD RU TJ TM

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH KE LS MW SD SZ UG ZW AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
NENP Non-entry into the national phase

Ref country code: JP

Ref document number: 98501866

Format of ref document f/p: F

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

NENP Non-entry into the national phase

Ref country code: CA

122 Ep: pct application non-entry in european phase